Takeda Drops Epilepsy Drug, Names New CEO Amid Q3 Earnings
In a news rush Thursday, Takeda announced it is stopping development and no longer seeking FDA approval for its epilepsy drug soticlestat, while naming a new chief executive alongside its third-quarter earnings report. In an SEC filing, the company stated …